Tm Bioscience Supplies Labcorp With Tag-It Cystic Fibrosis Reagents
News Oct 14, 2005
Tm Bioscience Corporation has announced that it is now supplying Laboratory Corporation of America Holdings with Tag-It CF70 reagents for use in their 70 mutation cystic fibrosis assay.
“We are delighted that LabCorp, one of the foremost providers of diagnostic testing in the U.S., has adopted additional products from our standardized Tag-It menu,” said Greg Hines, President and CEO of Tm Bioscience.
“Our CF70 reagents are the latest in a suite of products Tm has developed enabling high throughput laboratories to better serve the burgeoning CF market with more competitive and comprehensive offerings.”
“These reagents will allow LabCorp to serve additional segments of the ethnically diverse U.S. population.”
As previously announced, LabCorp has signed a master purchase agreement with Tm for the Company’s suite of Tag-It products.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.